GSA Capital Partners LLP Buys 231,260 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

GSA Capital Partners LLP raised its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 196.1% during the 1st quarter, Holdings Channel.com reports. The fund owned 349,204 shares of the biotechnology company’s stock after purchasing an additional 231,260 shares during the quarter. GSA Capital Partners LLP’s holdings in Aurinia Pharmaceuticals were worth $1,750,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lazard Asset Management LLC increased its position in shares of Aurinia Pharmaceuticals by 138.0% during the 3rd quarter. Lazard Asset Management LLC now owns 55,428 shares of the biotechnology company’s stock valued at $430,000 after purchasing an additional 32,137 shares during the last quarter. Graham Capital Management L.P. purchased a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at about $532,000. Hudson Bay Capital Management LP increased its position in shares of Aurinia Pharmaceuticals by 19.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 156,484 shares of the biotechnology company’s stock valued at $1,216,000 after purchasing an additional 25,000 shares during the last quarter. Sunbelt Securities Inc. increased its position in shares of Aurinia Pharmaceuticals by 154.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 196,090 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 118,990 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Aurinia Pharmaceuticals by 66.2% during the 4th quarter. SG Americas Securities LLC now owns 35,207 shares of the biotechnology company’s stock valued at $317,000 after purchasing an additional 14,025 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Trading Down 0.2 %

AUPH traded down $0.01 during trading on Wednesday, reaching $5.51. The company had a trading volume of 235,125 shares, compared to its average volume of 1,790,607. The stock has a market cap of $786.06 million, a P/E ratio of -12.84 and a beta of 1.44. The business has a 50 day simple moving average of $5.40 and a 200-day simple moving average of $6.14. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $12.43. The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.14. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. The business had revenue of $50.30 million for the quarter, compared to analyst estimates of $46.30 million. On average, equities analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.